Himalaya Liv.52 DS: The Ayurvedic Liver Supplement That Has Been in Indian Medicine Cabinets Since 1955 — 264 Clinical Studies, Eight Proven Herbs, and Why the Diaspora's Liver Needs It More Than Ever

In 1955, The Himalaya Drug Company launched Liv.52 — a hepatospecific Ayurvedic formulation combining Caper Bush, Wild Chicory, and six supporting herbs into a tablet specifically designed to protect, support, and restore liver function. Seventy years later, Liv.52 remains in continuous production, remains one of the most widely prescribed Ayurvedic supplements worldwide, and has accumulated what is, for any Ayurvedic product, an extraordinary body of clinical evidence: over 264 clinical studies across multiple countries, including randomised double-blind placebo-controlled trials. It is prescribed by Ayurvedic physicians, recommended by conventional physicians in India, and trusted by three generations of Indian families as the liver supplement that lives in the medicine cabinet alongside the paracetamol and the antacid.

Liv.52 DS (Double Strength) is the concentrated formulation — each tablet contains twice the active ingredient concentration of regular Liv.52, designed for the more specific clinical indications: nonalcoholic fatty liver disease (NAFLD), drug-induced liver injury (DILI), and the hepatoprotective support required when taking hepatotoxic medications like antitubercular drugs, statins, and antiretrovirals. For the Indian diaspora managing the liver challenges specific to diaspora life — the fatty liver from the Indian dietary pattern in an American sedentary environment, the medication-related liver burden of managing metabolic syndrome — Liv.52 DS on Swadesiicart provides access to the formulation that Indian physicians have been reaching for since Eisenhower's first term.

Himalaya's Liv.52 DS Tablets (Double Strength), available on Swadesiicart, is the 70-year-old hepatospecific Ayurvedic formulation from The Himalaya Drug Company — Himsra, Kasani, Mandur Bhasma, Kakamachi, Arjuna, and three supporting herbs — for NAFLD support, drug-induced liver protection, and comprehensive liver health maintenance, backed by 264 clinical studies.

Launched in 1955: Why Longevity Is Evidence

The year 1955 provides useful context for Liv.52's history: India had been independent for 8 years, and the modern pharmaceutical industry was still in its early decades. The Himalaya Drug Company, founded in 1930 in Dehradun, had been producing Ayurvedic medicines for 25 years when they launched Liv.52 — the first systematic attempt to create a clinically validated Ayurvedic liver supplement. The formulation's surviving seven decades of competition from both pharmaceutical and Ayurvedic alternatives is not inertia or brand loyalty alone. In a market where ineffective products are replaced and discontinued, continuous clinical use and physician prescription over 70 years is its own form of evidence.

The 264 clinical studies that Himalaya cites represent a body of evidence accumulated over this 70-year period — ranging from early Indian clinical reports to more recent randomised controlled trials in international journals. No other Ayurvedic liver supplement comes close to this depth of published clinical investigation. The formulation's continued AYUSH registration, its listing in the National Formulary of Ayurvedic Medicine, and its current indications on Himalaya's own website (NAFLD, DILI, hepatotoxic drug adjuvant) reflect contemporary evidence-based repositioning rather than historical marketing.

The 70-Year Validation: In 1955, Himalaya launched Liv.52. In 2025, it remains in continuous production with the same core formulation, actively prescribed and purchased. The product has outlasted dozens of pharmaceutical liver supplements that were launched, found inadequate, and discontinued in the same period. Seventy years of physician prescription is not coincidence.

Liv.52 DS vs. Regular Liv.52: When Double Strength Is Appropriate

The difference between regular Liv.52 and Liv.52 DS is quantitative rather than qualitative — the same eight ingredients at double the concentration per tablet. The clinical implication: DS is prescribed and recommended for more specific, more significant liver conditions and for adjuvant use with hepatotoxic medications, where the higher concentration of hepatoprotective actives is required:

•      Nonalcoholic Fatty Liver Disease (NAFLD): NAFLD is now the most prevalent liver condition in the Indian diaspora — the combination of the Indian dietary pattern (high refined carbohydrate, high saturated fat), the central adiposity of the South Asian metabolic phenotype, and insulin resistance produces fat deposition in the liver that progresses to NASH (nonalcoholic steatohepatitis) and can ultimately progress to cirrhosis. Himalaya specifically lists NAFLD as a primary Liv.52 DS indication.

•      Drug-Induced Liver Injury (DILI): Multiple medications commonly prescribed to the Indian diaspora managing metabolic syndrome cause hepatotoxicity: statins (prescribed for dyslipidaemia — the Lipomap audience on Swadesiicart), metformin at high doses, antitubercular drugs (TB remains elevated in the Indian diaspora), and antiretrovirals. Liv.52 DS as an adjuvant to these medications provides documented hepatoprotective support that reduces the transaminase elevations that these drugs produce.

•      Antitubercular therapy adjuvant: This is one of Liv.52 DS's most evidence-supported uses. Isoniazid, rifampicin, and pyrazinamide — the standard antitubercular drug regimen — produce significant hepatotoxicity in approximately 10-30% of treated patients. Indian physicians routinely prescribe Liv.52 (or Liv.52 DS for higher risk patients) alongside antitubercular therapy to reduce drug-induced liver injury.

Why the Indian Diaspora's Liver Is Specifically Under Pressure

The Indian diaspora's liver faces a specific set of challenges that converge from dietary, genetic, and medication-related directions:

•      NAFLD epidemic: NAFLD prevalence in South Asian populations is estimated at 24-29% — significantly higher than Western populations at equivalent BMI, driven by the same thin-fat Indian phenotype, genetic insulin resistance, and dietary carbohydrate burden described in the Amrith Noni D Plus blog. The diaspora's Indian dietary habits in an American sedentary environment produce particularly high NAFLD risk.

•      Statin use: The Indian diaspora's elevated cardiovascular risk (from metabolic syndrome and genetic dyslipidaemia) means a high proportion of diaspora adults above 40 are on statin therapy. Statins cause transaminase elevation in approximately 3% of patients and rare but serious liver injury. Liv.52 DS as a co-administered hepatoprotective supplement is a reasonable supportive measure under physician guidance.

•      Alcohol-associated liver damage: While Indian cultural norms around alcohol are complex and community-specific, alcohol consumption is present in a significant portion of the diaspora, and Indian genetic variants in alcohol dehydrogenase metabolism mean Indian drinkers are at elevated liver injury risk from equivalent alcohol consumption compared to European drinkers.

•      General metabolic burden: The combination of T2D, hypertension, and dyslipidaemia that characterises the Indian diaspora's metabolic syndrome cluster places cumulative metabolic stress on the liver as the central metabolic organ. Regular hepatoprotective support through Liv.52 DS addresses this cumulative burden.

The Eight Herbs: What Each One Does

Himsra (Capparis Spinosa / Caper Bush) 130mg — Primary Hepatoprotective

Caper Bush (Capparis spinosa) — the same capers used in Mediterranean cooking — is one of Ayurveda's most consistently documented liver herbs. Its isothiocyanate and flavonoid content provides documented hepatoprotective activity: it stabilises hepatic cell membranes against toxic damage, reduces lipid peroxidation in liver tissue, and has anti-inflammatory properties that address the hepatic inflammation component of NAFLD and DILI. At 130mg per DS tablet — the highest dose in the formula — Himsra anchors the hepatoprotective action.

Kasani (Cichorium Intybus / Wild Chicory) 130mg — Alcohol and Toxin Protection

Wild Chicory at 130mg shares the primary dosing position with Himsra. Chicory root's primary role in Liv.52 is specific to alcohol-induced liver damage — its compounds specifically protect against the hepatotoxicity of ethanol metabolism. Chicory also contains inulin (a prebiotic fibre that supports gut health and reduces the endotoxin burden on the liver from the gut), and its hepatoprotective activity extends to chemical toxins beyond alcohol. Its antioxidant flavonoids contribute to the formula's overall antioxidant hepatoprotection.

Mandur Bhasma (Iron Oxide Bhasma) 66mg — Haematopoietic and Metabolic

Mandur Bhasma — the Rasa Shastra preparation of iron oxide — provides the haematopoietic support that addresses the anaemia commonly associated with chronic liver disease, and contributes to the formula's general metabolic support. In the Liv.52 context, Mandur Bhasma supports the liver's iron metabolism function and the erythropoietin-related hepatic activity. This is the only Rasa Shastra ingredient in the Liv.52 DS formula, reflecting Himalaya's careful integration of classical Bhasma preparations into an otherwise herb-based formulation.

Kakamachi (Solanum Nigrum / Black Nightshade) 64mg — Hepatocellular Regeneration

Solanum nigrum (Black Nightshade — also called Kakmachi) is one of the classical Ayurvedic liver herbs with documented hepatoprotective and hepato-regenerative properties. Its steroidal alkaloids (solasonine, solamargine) and glycoalkaloids have published evidence for stimulating hepatocellular regeneration — the replacement of damaged liver cells with functional hepatocytes. This regenerative action is specifically relevant for post-hepatitis and DILI recovery.

Arjuna (Terminalia Arjuna) 64mg — Antioxidant and Cardioprotective

Arjuna is best known in Ayurveda as the heart herb — its triterpenoid glycosides have documented cardioprotective and antioxidant properties. In Liv.52 DS, Arjuna contributes its antioxidant action to hepatic protection (the liver and cardiovascular system are metabolically interconnected — NAFLD is now understood as a hepatic manifestation of metabolic syndrome that drives cardiovascular risk), and its anti-inflammatory flavonoids support the reduction of hepatic inflammation.

Kasamarda, Biranjasipha, and Jhavuka 32mg Each — Supporting Anti-inflammatory

The three 32mg supporting herbs — Kasamarda (Cassia occidentalis / Coffee Senna), Biranjasipha (Achillea millefolium / Yarrow), and Jhavuka (Tamarix gallica / French Tamarisk) — provide the anti-inflammatory, antimicrobial, and antioxidant completion of the formula's hepatoprotective action. Yarrow's anti-inflammatory flavonoids, Cassia's liver-protective anthraquinones, and Tamarisk's polyphenol antioxidants fill the supporting roles that the higher-dose primary herbs require.

Dosage

STANDARD DOSAGE: 1-2 tablets twice daily after meals, with water. The DS (Double Strength) formulation is typically prescribed at 1 tablet twice daily for preventive and supportive use (NAFLD prevention, statin co-administration), and 2 tablets twice daily for more active conditions (DILI treatment, post-hepatitis recovery) under physician guidance. For antitubercular therapy adjuvant use: begin Liv.52 DS at the time the antitubercular regimen starts, not after hepatotoxicity has already developed. Duration: Himalaya confirms safe use for a minimum of 6 months; longer duration is appropriate for chronic conditions under physician oversight.

Liv.52 DS Complete Composition

INTERNAL LINKING SUGGESTIONS:

•      Link [https://swadesiicart.com/products/himalaya-liv-52-ds-tablets-double-strength?_pos=1&_psq=Himalaya+Liv.52+DS+Tablets+%E2%80%93+Double+Strength+Ayurvedic+Liver+Protection+%26+Detox&_ss=e&_v=1.0] 

Frequently Asked Questions About Himalaya Liv.52 DS

Q1. My doctor put me on a statin for cholesterol. Should I take Liv.52 DS alongside it?

This is one of the most specific and well-supported use cases for Liv.52 DS. Statins (atorvastatin, rosuvastatin, simvastatin) cause transaminase elevation (elevated liver enzymes) in approximately 3% of patients — a sign of hepatocellular stress from the drug's metabolism in the liver. Severe statin-induced liver injury is rare but does occur. Indian physicians routinely co-prescribe Liv.52 or Liv.52 DS with statin therapy to provide hepatoprotective support, and this practice is supported by the clinical trial evidence for Liv.52's DILI prevention efficacy. However, you should discuss this co-administration with your prescribing physician before beginning — your physician may prefer to monitor your liver enzymes at baseline and after 3 months of statin use, and add Liv.52 DS if transaminase elevation is observed, rather than prophylactically. Inform your physician if you are taking any Ayurvedic supplement alongside prescribed medications.

Q2. I have been told I have a fatty liver (NAFLD). Is Liv.52 DS appropriate?

NAFLD is one of the primary indications that Himalaya lists for Liv.52 DS on their own product page. The clinical rationale is that Himsra's hepatocellular membrane protection and Kasani's antioxidant action reduce the lipid peroxidation that drives the progression from simple fatty liver (steatosis) to inflammatory NASH and ultimately to fibrosis. The clinical evidence from Himalaya's 264 studies includes NAFLD-specific trials. That said, NAFLD management requires a physician's oversight — the lifestyle interventions of weight reduction (even 5-7% of body weight significantly reduces hepatic fat), dietary carbohydrate reduction, and increased physical activity are the primary NAFLD treatments. Liv.52 DS is a supportive measure alongside these lifestyle interventions, not a replacement for them. Discuss with your physician or gastroenterologist before starting.

Q3. What is the difference between Liv.52 and Liv.52 DS? Which should I choose?

Regular Liv.52 contains the same eight herbs at half the concentration of Liv.52 DS. Regular Liv.52 is appropriate for: general preventive liver health maintenance, mild digestive disorders, loss of appetite, and as a general tonic for those with no specific diagnosed liver condition. Liv.52 DS at double strength is appropriate for: diagnosed NAFLD, drug-induced liver injury, co-administration with hepatotoxic medications (statins, antitubercular drugs, antiretrovirals), post-hepatitis recovery, and pre-cirrhotic conditions. If you have a specific diagnosed liver condition or are on hepatotoxic medication, Liv.52 DS is the appropriate formulation. For general liver wellness maintenance in a healthy individual, regular Liv.52 is adequate and more gentle.

Q4. Can I take Liv.52 DS long-term? Are there any cumulative side effects?

Himalaya's own documentation states that Liv.52 DS 'is not known to have any significant adverse reaction or serious adverse event if taken as per the prescribed dosage' and that it can safely be taken for a minimum of 6 months. Long-term use (beyond 6 months) under physician oversight is documented as safe. The one consideration for extended use is the Mandur Bhasma (iron oxide) component — those with hereditary haemochromatosis or other iron overload conditions should discuss with their physician whether the iron content is appropriate for extended use. For the vast majority of healthy adults without iron overload conditions, Liv.52 DS is considered safe for extended courses at prescribed doses.

70 Years. 264 Clinical Studies. Eight Herbs. The Liver Supplement Three Generations of Indian Families Have Trusted.

The Indian physician who prescribed Liv.52 to your grandfather in 1975 was using the same eight-herb formulation that is available on Swadesiicart today. The compound has not needed to change because the clinical evidence that accumulated over 70 years has consistently confirmed what the original Himalaya formulation team assembled in 1955: Himsra and Kasani as the hepatoprotective backbone, Arjuna and Mandur Bhasma for antioxidant and metabolic support, Kakamachi for cellular regeneration, and three supporting anti-inflammatory herbs — all working together to protect, support, and restore the liver that the Indian diaspora's dietary pattern, medication burden, and metabolic challenges put under daily pressure.

For the diaspora adult who is on a statin, managing NAFLD, taking antitubercular medication, or simply maintaining the liver health of a body navigating the specific metabolic challenges of the South Asian constitution in an American environment — Liv.52 DS on Swadesiicart is the same product that Indian physicians have been prescribing for seven decades.

Himsra 130mg + Kasani 130mg + Mandur Bhasma 66mg + Kakamachi 64mg + Arjuna 64mg + three supporting herbs. Double strength. Hepatoprotective. NAFLD. DILI. Statin adjuvant. Antitubercular adjuvant. 264 clinical studies. Himalaya Drug Company since 1955. 1-2 tablets twice daily after meals. Physician consultation recommended. Shop Himalaya Liv.52 DS on Swadesiicart now — free shipping on orders above $55, SSL-secured checkout, and 14-day hassle-free returns.

The Himalaya Drug Company / Himalaya Wellness   |   Liv.52 DS Tablets (Double Strength)   |   Himsra + Kasani + Mandur Bhasma + Kakamachi + Arjuna + 3 supporting herbs   |   NAFLD | DILI | Statin Adjuvant | Antitubercular Adjuvant   |   1-2 Tablets Twice Daily After Meals   |   Launched 1955   |   264 Clinical Studies